Celldex Therapeutics Inc (NASDAQ: CLDX) on Tuesday, soared 7.50% from the previous trading day, before settling in for the closing price of $22.67. Within the past 52 weeks, CLDX’s price has moved between $14.40 and $29.05.
A company in the Healthcare sector has jumped its sales by 6.91% annually for the last half of the decade. The company achieved an average annual earnings per share of -48.99%. With a float of $64.52 million, this company’s outstanding shares have now reached $66.45 million.
Celldex Therapeutics Inc (CLDX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Celldex Therapeutics Inc is 2.84%, while institutional ownership is 111.80%. The most recent insider transaction that took place on Aug 13 ’25, was worth 19,096. In this transaction SVP & GENERAL COUNSEL of this company sold 771 shares at a rate of $24.77, taking the stock ownership to the 34,962 shares.
Celldex Therapeutics Inc (CLDX) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.71 earnings per share (EPS) for the period topping the consensus outlook (set at -0.71) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -48.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -22.28% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Celldex Therapeutics Inc (CLDX) is currently performing well based on its current performance indicators. A quick ratio of 13.01 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 622.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.42 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.08 million. That was better than the volume of 1.02 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 21.16%.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 53.47%, which indicates a significant increase from 39.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.17 in the past 14 days, which was lower than the 1.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.48, while its 200-day Moving Average is $22.07. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $25.39. Second resistance stands at $26.42. The third major resistance level sits at $28.06. If the price goes on to break the first support level at $22.72, it is likely to go to the next support level at $21.08. Assuming the price breaks the second support level, the third support level stands at $20.05.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
Market capitalization of the company is 1.62 billion based on 66,407K outstanding shares. Right now, sales total 7,020 K and income totals -157,860 K. The company made 730 K in profit during its latest quarter, and -56,600 K in sales during its previous quarter.
